The Zimbabwe National Pharmacovigilance Policy Handbook, 2nd Edition updates the November 2013 version to indicate the Zimbabwe National Pharmacovigilance (PV) Centre’s compliance with the WHO Pharmacovigilance Indicators Handbook 2015.
Accessed: 08.10.2019
Based on the National Guidelines for the Management of Tuberculosis in Children 2013, Department of Health, South Africa.
A review of prospects for existing antibiotics ad new therapeutics
Chapter in Clinical guidelines -Diagnosis and Treatment manual
Le flyer „MMV Strategy“ présente la stratégie de la Medicines for Malaria Venture (MMV) pour lutter contre le paludisme. Il met en avant les objectifs clés de l'organisation, qui se concentre sur la recherche et le développement de nouveaux médicaments antipaludiques. Le document décrit le...s efforts pour améliorer l'accès aux traitements de qualité, soutenir les partenariats mondiaux, et accélérer l'innovation dans la lutte contre le paludisme, avec un accent particulier sur les populations à risque élevé.
more
The safety of medicines in Zambia - why health workers need to take action | Produced by the National Pharmacovigilance Unit (NPVU)
First edition, November 1997 | Revised July 2002
An overview of COVID-19 Vaccine AstraZeneca and why it is authorised in the EU. Available in 22 languages
18 Febr. 2021
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more
The European Medicines Agency (EMA) is evaluating potential COVID-19 treatments and vaccines to enable promising medicines to reach patients as soon as possible. It is also interacting with medicine developers and making use of real-world data to monitor the safety and effectiveness of medicines use...d in patients with COVID-19.
more
Guidance for the preparation and submission of dossiers